USPTO Patents Application 10551504

COPY SUBMITTED IN IDS

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2006/3 11600

A. CLASSIFICATION OF SUBJECT MATTER

A61K39/395 (2006 .01) i , A61K9/19 (2006 . 01) i , A62K47/02 (2006 . 01) i , A61K47/10
(2006. 01)i, A61K47/18 (2006 . 01) i , 7/22 (2006 . 01) i , A61K4 7/26 (2006 . 0 1 ) i ,

A62fT4 7/4 6(2006 . 01) i, A61 P43/00 (2006 . 01 ) i , G01N33/15 (2006 . 01) i ,
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K39/395 (2006 . 01) , A61K9/19 (2006 . 01) , A61K4 7/02 (2006 . 01) , A62fC47/20
(2006.01), A61K47/18 {2006 . 01) , Ae52fC4 7/22 (2006 . 01 ) , A62i?47/26(2006 . 01) ,
A61K47/46{2006 . 01) , A&2P4.3/00 (2006 . 01) , G01N33/15 (2006 . 01) ,

Documentation searched other than niinimum documentation to the extent that such documents are included in the fields searched
Jitsuyo Shinan Kbho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2006

Kokai Jitsuyo Shinan Koho 1971-2006 Toroku Jitsuyo Shinan Koho 1994-2006

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAplus (STN) , EMBASE (STN) , MEDLINE (STN) , JMEDPlus < JDream2) ,
JST7580 (JDream2) , JSTPlus ( JDream2)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*

Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

X

COCHLOVIUS B . , Treatment of human B cell

1-6,9, 14-19,

lymphoma xenografts with a CD3 x CD19 diabody

22

Y

and T cells. Journal of immunology, 2000,

10

A

vol.165. No. 2, pages 888 to 895

12 , 13 , 23 , 24 ,

36-42

Y

WO 2004/019966 Al (CHUGAI SEIYAKU KABUSHIKI

10

KAISHA) ,

11 March, 2004 (11.03.04),

Full text

& EP 1541165 Al & US 2006/058511 Al

I x I Further documents are listed in the continuation of Box C. [ I See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to

be of particular relevance
"E" earlier application or patent but published on or after the international filing

date

"L" document which may throw doubts on priority claim(s) or which is
cited to establish the publication date of another citation or other
special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later tian the
priority date claimed

Date of the actual completion of the international search
[ 17 August, 2006 (17.0 8.06)

Date of mailing of the international search report
29 August, 2006 (29.08.06)

Name and mailing address of the ISA'

Japanese Patent Office

Facsimile No.

Authorized officer
Telephone No.

Form PCT/ISA/210 (second sheet) (April 2005)

"T* later document published after tie international filing date or priority
date and not in conflict with the application but cited to understand
the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be
considered novel or cannot be considered to involve an inventive
step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be
considered to involve an inventive step when the document is
combined with one or more other such documents, such combination
being obvious to a person skilled in the art

■ document member of the same patent family

COPY SUBMITTED IN IDS

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2 006/3 11600

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*

Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

Y

JP 2003-515323 A (OXFORD BIOMEDICA (UK) LTD.),
07 May, 2003 (07.05.03),
Claims; Par. No. [02 08]

& WO 2001/36486 A2 & EP 1242456 A2

& US 2003/083290 Al . & US 2004/131591 Al

&. US 2004/265275 Al & US 2006/014222 Al

10

Y

JP 2002-543822 A (SMITHKLINE BEECHAM CORP., US),
24 December, 2002 (24.12.02),
Par. Nos. [0020], [0075]

& WO 2000/69462 Al & EP 1178829 Al

10

P,X

WO 2005/107784 Al (CHUGAI SEIYAKU KABUSHIKI
KAISHA, JP) ,

17 November, 2005 (17.11.05),
Par. No. [0147] ; example 1
(Family: none)

1-6,9, 14-19,
22

A

KIPRIYANOV S.M., Bispecific tandem diabody for
tumor therapy with improved antigen binding
and pharmacokinetics. Journal of Molecular
Biology, 1999, Vol.293, No.l, pages 41 to 56

12,13,23,24,
36-42

A

Voelkel T., Optimized linker sequences for the
expression of monomeric and dimeric bispecific
single-chain diabodies, Protein Engineering,
2001, Vol.14, No. 10, pages 815 to 823

12,13,23,24,
36-42

A

Meng R . , The evaluation of recombinant, chimeric,
tetravalent antihuman CD22 antibodies. Clinical
cancer research, 2 0 04, vol.10. No. 4, pages 1274
to 12 81

12, 13,23, 24,
36-42

A

JAGER M . , Folding and Assembly of an Antibody
Fv Fragment, a Heterodimer Stabilized by Antigen,
Journal of Molecular Biology, 1999, Vol.285,
No. 5, pages 2005 to 2019

12,13,23,24,
36-42

A

KORN T., Recombinant bispecific antibodies
for the targeting of adenoviruses to CEA-
expressing tumour cells: a comparative analysis
of bacterially expressed single-chain diabody
and tandem scFv, Journal of Gene Medicine,
2 0 04, Vol.6, No. 6, pages 642 to 651

12,13,23,24,
36-42

A

KIPRIYANOV S.M., Effect of Domain Order on the
Activity of Bacterially Produced Bispecific
Single -chain Fv Antibodies, Journal of Molecular
Biology, 2003, Vol.330, No.l, pages 99 to 111

12, 13, 23, 24,
36-42

Form PCT/ISA/210 (continuation of second sheet) (April 2005)